0000899243-23-018762.txt : 20230912
0000899243-23-018762.hdr.sgml : 20230912
20230912182024
ACCESSION NUMBER: 0000899243-23-018762
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230908
FILED AS OF DATE: 20230912
DATE AS OF CHANGE: 20230912
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perkins Adelene Q
CENTRAL INDEX KEY: 0001375124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 231251219
MAIL ADDRESS:
STREET 1: C/O INFINITY PHARMACEUTICALS, INC.
STREET 2: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 MASSACHUSETTS AVENUE
STREET 2: FLOOR 4
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 1100 MASSACHUSETTS AVENUE
STREET 2: FLOOR 4
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-08
0
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001375124
Perkins Adelene Q
C/O INFINITY PHARMACEUTICALS, INC.
1100 MASSACHUSETTS AVENUE, FLOOR 4
CAMBRIDGE
MA
02138
1
0
0
0
1
Common Stock
2023-09-09
4
M
0
768133
A
1585487
D
Common Stock
2023-09-12
4
S
0
410196
0.07
D
1175291
D
Common Stock
16446.7945
I
401(K)
Restricted Stock Unit
2023-09-09
4
M
0
768133
0.00
D
Common Stock
768133
0
D
Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.
/s/ Adelene Q. Perkins
2023-09-12